PacBio Q4 revenue down 24% YoY to $27.4M; net loss $84.4M; record Revio orders

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

2022-FY EPS reported -$1.40 revenue$128,304,000

Q4 2022 GAAP net loss $84.4M ($0.37 EPS) vs $69.3M loss ($0.31 EPS) a year ago.
Revenue $27.4M, down 24% YoY; instrument revenue fell 62% to $6.1M.
Record orders for 96 instruments, including 76 Revio systems from 43 customers.
Gross margin fell to 19% from 47%, impacted by $7.1M loss on purchase commitments.
Raised ~$201M in January 2023 public offering; Revio commercial shipments begin March 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported financial results for fourth fiscal quarter and year ended December 31, 2022.

Period: fourth fiscal quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 16, 2023, Pacific Biosciences of California, Inc. (the “Company”) announced its financial results for its fourth fiscal quarter and year ended December 31, 2022. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filing history →

Source: SEC EDGAR

accession 0001299130-23-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.